Literature DB >> 21475952

Emerging treatment options for benign prostatic obstruction.

Brian A Parsons1, Hashim Hashim.   

Abstract

Benign prostatic obstruction (BPO) affects an increasing number of men with age. It can cause troublesome lower urinary tract symptoms, can have a negative impact on quality of life, and may be associated with significant morbidity. Currently available medication and surgical treatments are limited by adverse events, invasiveness, and patient compliance. This has driven research into the pathogenesis of benign prostatic hyperplasia and led to the development of novel pharmacological agents and minimally invasive therapeutic interventions. This review highlights emerging treatment options for BPO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21475952     DOI: 10.1007/s11934-011-0190-4

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  52 in total

Review 1.  Adventures of a pore-forming toxin at the target cell surface.

Authors:  L Abrami; M Fivaz; F G van der Goot
Journal:  Trends Microbiol       Date:  2000-04       Impact factor: 17.079

Review 2.  Transurethral resection of the prostate revisited and updated.

Authors:  R Daron Smith; Anup Patel
Journal:  Curr Opin Urol       Date:  2011-01       Impact factor: 2.309

Review 3.  Benign prostate hyperplasia: a review of the year's progress from bench to clinic.

Authors:  Robert F Donnell
Journal:  Curr Opin Urol       Date:  2011-01       Impact factor: 2.309

4.  BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.

Authors:  Enrico Colli; Patrizio Rigatti; Francesco Montorsi; Walter Artibani; Stefano Petta; Nicola Mondaini; Roberto Scarpa; Paolo Usai; Lorenza Olivieri; Mario Maggi
Journal:  Eur Urol       Date:  2005-11-15       Impact factor: 20.096

5.  Effects of nitric oxide on human and canine prostates.

Authors:  M Takeda; R Tang; E Shapiro; A L Burnett; H Lepor
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

6.  High power diode laser vaporization of the prostate: preliminary results for benign prostatic hyperplasia.

Authors:  Ali Erol; Kamil Cam; Ali Tekin; Omur Memik; Soner Coban; Yavuz Ozer
Journal:  J Urol       Date:  2009-07-18       Impact factor: 7.450

7.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

8.  Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.

Authors:  D Gonzalez-Barcena; M Vadillo-Buenfil; F Gomez-Orta; M Fuentes Garcia; I Cardenas-Cornejo; A Graef-Sanchez; A M Comaru-Schally; A V Schally
Journal:  Prostate       Date:  1994       Impact factor: 4.104

9.  Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle.

Authors:  E Shapiro; V Hartanto; H Lepor
Journal:  Prostate       Date:  1992       Impact factor: 4.104

10.  Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.

Authors:  Ian W Mills; Anna Crossland; Anup Patel; Henrikas Ramonas
Journal:  Eur Urol       Date:  2007-02-20       Impact factor: 20.096

View more
  2 in total

1.  Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies.

Authors:  Neil F Wasserman; Benjamin Spilseth; Jafar Golzarian; Gregory J Metzger
Journal:  AJR Am J Roentgenol       Date:  2015-09       Impact factor: 3.959

2.  The value of respective urodynamic parameters for evaluating the occurrence of complications linked to benign prostatic enlargement.

Authors:  Xingliang Yang; Kai Wang; Jiang Zhao; Wei Yu; Longkun Li
Journal:  Int Urol Nephrol       Date:  2014-05-09       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.